Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Ultra Short Income ETF (JPST) vs Mesoblast Limited (MESO) Price & Performance

JPMorgan Ultra Short Income ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

JPMorgan Ultra Short Income ETF vs Mesoblast Limited — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.46, while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Mesoblast Limited is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.

JPSTMESO
Sector
Leveraged / InverseTechnology
52-Week High
$50.78$20.96
52-Week Low
$50.40$12.88
Market Cap
$2.16B
Enterprise Value
$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Ultra Short Income ETF

JPST (JPMorgan Ultra-Short Income ETF) trades at $50.44, showing minimal daily movement with a 0.08% gain. The technical picture remains bearish with moving averages signaling caution, though the RSI suggests potential oversold conditions. Recent institutional activity shows growing interest, with Financial Management Professionals increasing their stake by 4.7% in Q2 2026. The fund maintains consistent dividend distributions of $0.17 per share, providing stable income for risk-averse investors seeking short-term bond exposure.

As an ultra-short income ETF, JPST offers conservative investors a cash-alternative with slightly higher yields than T-bills. The fund's stability and consistent dividends make it attractive for parking cash between investments or during uncertain rate environments. However, rising interest rates and inflation pressures pose headwinds for short-term bond performance. The ETF's bearish technical signals warrant monitoring, though its defensive positioning provides downside protection in volatile markets.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About JPMorgan Ultra Short Income ETF

JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.

Read more on JPST

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO